Targeted Radiotherapies for Patients with Unmet Needs: A Conversation with Actinium Pharmaceuticals CEO Sandesh Seth

    Sandesh Seth, CEO of Actinium Pharmaceuticals which is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs joins eHealth Radio and the <a href="https://ehealthradio.podbean.com/category/cancer-information" target="_blank" rel="noreferrer noopener">Cancer Information</a> and <a href="https://ehealthradio.podbean.com/category/health-news" target="_blank" rel="noreferrer noopener">Health News</a> Channels. Listen to interview with host <a href="https://www.linkedin.com/in/ericmdye/" target="_blank" rel="noreferrer noopener">Eric Michaels</a> and guest Sandesh Seth discuss the following: <ol><li>What is unique about Actinium’s radiotherapy approach?</li><li>Tell me about Iomab-B, its target population, and how it will affect the patient journey.</li><li>Actimab-A is also in AML. How is it different from Iomab-B and what’s the approach here?</li><li>What’s next in your pipeline?</li><li>Tell me what upcoming catalysts I should expect in the second half of 2023.</li></ol>About Actinium Pharmaceuticals, Inc. <a href="https://www.actiniumpharma.com" target="_blank" rel="noreferrer noopener">Actinium Pharmaceuticals</a> develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an induction and conditioning agent prior to bone marrow transplant, and Actimab-A (National Cancer Institute CRADA pivotal development path), a therapeutic, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. Actinium's technology platform is the basis for collaborations with Astellas Pharma for solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3 solid tumors, and EpicentRx for